People
It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.
Last year, Novartis’ multiple sclerosis drug Gilenya generated more than $3 billion in revenue, with a little more than half of that coming from sales in the United States. As the drug faces patent loss in the future, Novartis is fighting to preserve that revenue driver with multiple lawsuits.
In a speech given at the Brookings Institution preceding the release of the U.S. Food and Drug Administration (FDA)’s Biosimilars Action Plan, FDA Commissioner Scott Gottlieb unloaded on big pharma.
Atul Gawande is heading out to hold one-on-one meetings with employees of a new healthcare venture to get a handle on their healthcare needs, challenges and concerns.
French biotech company Servier is setting up shop in Boston following its April deal to acquire Shire’s oncology business for $2.4 billion.
Seattle-based Presage Biosciences made several key moves today that include a $6 million investment from pharma giants Takeda and Celgene and also tapped a new chief executive officer.
Two well-known pharmaceutical companies made Fortune Magazine’s 2018 top 100 Best Workplaces for Millennials.
With the Independence Day holiday in the rearview mirror, numerous biopharma companies continued to adjust their leadership ranks and strengthen the members of various boards representing and overseeing the companies.
Saturnino “Nino” Fanlo, chief financial officer and chief operations officer of Human Longevity (HLI), has left the company. Fanlo was implicated in a scandal at his previous employer, online lender Social Finance (SoFi).
Novartis and Michael Cohen, attorney to President Donald Trump, had a much deeper relationship than has been previously disclosed and was selling access to the White House, a new report issued by Senate Democrats alleges.
PRESS RELEASES